Nephrology Medical News about Rosiglitazone

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 06/23/09

Lennon R et al. - Rosiglitazone has a direct and protective effect on glucose uptake in wild-type human podocytes. This represents a novel mechanism by which PPAR-gamma agonists may improve podocyte function in diabetic nephropathy.

Exclusive Author Commentary
M. A. Saleem, 06/23/09

The podocyte is increasingly being seen as central to the pathogenesis of diabetic nephropathy. Insulin sensitivity in glomerular podocytes is a novel and important finding in the context of understanding the pathogenesis of diabetic nephropathy. A key question is whether this cellular insulin sensitivity is lost in type II diabetes, as is seen in other insulin sensitive tissues, and therefore whether drugs can improve this sensitivity. This study for the first time demonstrates that podocytes can become insulin resistant, and that the PPARgamma class of drugs counteracts the effect, and in themselves improve podocyte insulin sensitivity.

<< Previous
Spectral diagnosis and analysis of a superior vesical artery...

Next >>
Chronic Kidney Disease, Transplantation Practices and...